title: Adrenal surgery for oligometastatic tumors improves survival in selected cases.
abstract: BACKGROUND
  Oligometastatic cancer prognosis is distinct from polymetastatic cancer prognosis and surgery can improve survival. The objective of this study was to assess the role of adrenalectomy and to look for prognostic or predictive factors for the treatment of patients with oligometastatic solid tumors and adrenal metastasis.
  
  
  METHODS
  Patients with oligometastatic solid tumors undergoing adrenalectomy were selected. Clinical data were retrieved from electronic patients records. Progression-free survival (PFS), overall survival (OS) and clinical outcomes were assessed.
  
  
  RESULTS
  Forty patients were analyzed. Median PFS was 7.4 months and PFS was longer for metachronous versus synchronous adrenal metastasis (10.8 versus 4.5 months; P=0.008). Median OS was 22.8 months and OS was better with laparoscopic adrenalectomy versus open adrenalectomy (24.4 versus 11.2 months; P=0.05).
  
  
  CONCLUSIONS
  Adrenalectomy part of the treatment plan of oligometastatic solid tumors but patients have to be selected. Surgery might be indicated for metachronous metastasis when laparoscopic adrenalectomy is possible.
authors.affiliation: Aix Marseille university, Assistance publique-Hôpitaux de Marseille, multidisciplinary oncology & therapeutic innovations department, 13015 Marseille, France; Aix Marseille university, Inserm U911 CRO2, 13005 Marseille, France. Electronic address: pascale.tomasini@ap-hm.fr.
authors.forename: P
authors.initials: P
authors.lastname: Tomasini
authors.affiliation: Aix Marseille university, Assistance publique-Hôpitaux de Marseille, multidisciplinary oncology & therapeutic innovations department, 13015 Marseille, France.
authors.forename: M-E
authors.initials: ME
authors.lastname: Garcia
authors.affiliation: Aix Marseille university, Assistance publique-Hôpitaux de Marseille, multidisciplinary oncology & therapeutic innovations department, 13015 Marseille, France; Aix Marseille university, Inserm U911 CRO2, 13005 Marseille, France.
authors.forename: L
authors.initials: L
authors.lastname: Greillier
authors.affiliation: Aix Marseille university, Assistance publique-Hôpitaux de Marseille, endocrine surgery department, 13005 Marseille, France.
authors.forename: C
authors.initials: C
authors.lastname: Paladino
authors.affiliation: Aix Marseille university, Assistance publique-Hôpitaux de Marseille, endocrine surgery department, 13005 Marseille, France.
authors.forename: F
authors.initials: F
authors.lastname: Sebag
authors.affiliation: Aix Marseille university, Assistance publique-Hôpitaux de Marseille, multidisciplinary oncology & therapeutic innovations department, 13015 Marseille, France; Aix Marseille university, Inserm U911 CRO2, 13005 Marseille, France.
authors.forename: F
authors.initials: F
authors.lastname: Barlesi
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D000315:Adrenalectomy; D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology*; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis
keywords: Adrenal metastasis; Adrenalectomy; Oligometastatic; Predictive factor; Prognostic factor